Kommentar zu „Unterbrechung einer langfristigen Betablocker-Therapie bringt keinen Vorteil“

• Literatur

• 1 Silvain J, Cayla G, Ferrari E. et al. Beta-Blocker Interruption or Continuation after Myocardial Infarction. The New England journal of medicine 2024; 391: 1277-1286
• 2 A Randomized Trial of Propranolol in Patients With Acute Myocardial Infarction: I. Mortality Results. Jama 1982; 247: 1707-1714
• 3 Puymirat E, Riant E, Aissaoui N. et al. Beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. Bmj 2016; 354: i4801
• 4 Holt A, Blanche P, Zareini B. et al. Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study. European heart journal 2021; 42: 907-914
• 5 Rossello X, Raposeiras-Roubin S, Latini R. et al. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). Eur Heart J Cardiovasc Pharmacother 2022; 8: 291-301
• 6 Choi KH, Kim J, Kang D. et al. Discontinuation of beta-blocker therapy in stabilised patients after acute myocardial infarction (SMART-DECISION): rationale and design of the randomised controlled trial. BMJ Open 2024; 14
• 7 Munkhaugen J, Ruddox V, Halvorsen S. et al. BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study. American heart journal 2019; 208: 37-46
• 8 Kristensen AMD, Bovin A, Zwisler AD. et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. Trials 2020; 21: 415